Medical/Pharmaceuticals
Wellcome and the Gates Foundation to Fund Late-Stage Development of a Tuberculosis Vaccine Candidate That Could Be the First in 100 Years If Proven Effective
TB is one of the world's deadliest diseases, killing about 4,300 people per day, mostly those living in poverty LONDON and SEATTLE, June 29, 2023 /PRNewswire/ -- Wellcome and the Bill & Melinda Gates Foundation today announced funding to advance a tuberculosis (TB) vaccine candidate, M72/AS01E ...
2023-06-29 00:00
4145
Babies Bliss Introduces Comprehensive Fertility Wellness Programme to Enhance Reproductive Health and Conception Journey
SINGAPORE, June 28, 2023 /PRNewswire/ -- Babies Bliss, a Singapore-based fertility wellness centre, is proud to announce its innovative fertility wellness programme designed to support women in improving their reproductive health and preparing their bodies for conception. The comprehensive progra...
2023-06-28 18:44
3252
European Society of Hypertension Announces Comprehensive New Guidelines for the Management of Arterial Hypertension
MILAN, June 28, 2023 /PRNewswire/ -- The European Society of Hypertension (ESH), the leading hypertension society inEurope, released updated and expanded 2023 ESH Guidelines for the Management of Arterial Hypertension during three oral presentations atthe 32nd Annual European Meeting on Hypertens...
2023-06-28 18:00
9554
Lo.Li. Pharma International and its International Partners Achieve a New World Record to Raise Awareness About Innovative Options for Managing PCOS and Infertility
COPENHAGEN, Denmark, June 28, 2023 /PRNewswire/ -- The Society of Human Reproduction and Embryology (ESHRE) annual meeting witnessed a historic event as people from around the globe gathered both in person and online to set a new world record for the most people consuming a dose of inositol simul...
2023-06-28 17:25
3583
Nuance Pharma's Partner Verona Pharma Submits New Drug Application to US FDA for Ensifentrine for the Maintenance Treatment of COPD
SHANGHAI, June 28, 2023 /PRNewswire/ -- Nuance Pharma announces its partner, Verona Pharma plc (Nasdaq: VRNA), has submitted a New Drug Application ("NDA") to the US Food and Drug Administration ("FDA") for approval of ensifentrine for the maintenance treatment of patients with chronic obstructi...
2023-06-28 17:07
6517
First Drug Discovered and Designed with Generative AI Enters Phase II Trials, with First Patients Dosed
* After completing the Phase 0 and Phase I human safety studies, INS018_055, Insilico's AI-discovered and AI-generated drug, has entered multi-regional Phase II clinical trials in the U.S andChina. * The first human patients were dosed with the drug. * This is a potentially first-in-class an...
2023-06-27 21:00
5757
TMRW Life Sciences Names Louis Villalba Chief Executive Officer
Seasoned Executive Appointed to Lead Fast-Growing Technology Company as It Signs 50 Fertility Clinics Representing Nearly 20% Market Share NEW YORK, June 27, 2023 /PRNewswire/ -- Today, TMRW Life Sciences, Inc. ("TMRW"), a fertility technology company automating the IVF lab, appointedLouis Villa...
2023-06-27 20:00
2471
Pharmadule Morimatsu and WuXi Biologics Reached Global Strategic Partnership
SHANGHAI, June 27, 2023 /PRNewswire/ -- June 26th, 2023, Pharmadule Morimatsu
and WuXi Biologics officially entered into a global strategic cooperation for
the Singapore CRDMO Center project of WuXi Biologics.
2023-06-27 15:33
5420
Lion TCR Secures USD 40 million Series B2 Financing, Revolutionizing Solid Tumor Treatment with mRNA-Encoding TCR-T Cell Therapy
SINGAPORE and GUANGZHOU, China, June 27, 2023 /PRNewswire/ -- 27 June 2023, Lion TCR, a clinical-stage T-cell immunotherapy company, is thrilled to announce the successful completion of itsUSD 40 million Series B2 financing round. Guangzhou Industrial Investment and Capital Operation Holding Grou...
2023-06-27 08:30
5503
CStone announces GAVRETO® (pralsetinib) sNDA approval by China NMPA for first-line treatment of patients with locally advanced or metastatic RET fusion-positive non-small cell lung cancer
* The approval for the first-line treatment of RET fusion-positive non-small cell lung cancer marks the third indication of GAVRETO in Mainland China, and the eleventh new drug application approval that CStone has obtained inGreater China overall. * In the ARROW study, GAVRETO had demonstrate...
2023-06-27 08:05
4586
New ZIRCON Phase III Data Presented at SNMMI: Potential Utility of TLX250-CDx in Staging and Monitoring ccRCC
MELBOURNE, Australia, June 27, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces further details of the positive results from its completed pivotal Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRC...
2023-06-27 03:51
3222
DentalMonitoring reinvents the scan experience
PARIS and AUSTIN, Texas, June 26, 2023 /PRNewswire/ -- DentalMonitoring announces their latest innovation, ScanAssist, the only AI-guided scan process available in orthodontics, designed to provide a fun, engaging patient experience, while also providing unprecedented photo quality for clinical ...
2023-06-26 23:43
3727
CXR-AID, Powered by Lunit, Nets Japan Nod for Reimbursement, Accelerating Market Expansion Opportunities
- Medical AI solutions, including CXR-AID, officially included in Japanese health insurance reimbursement as a management service fee of imaging diagnosis SEOUL, South Korea, June 26, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a global provider of cancer diagnostics solutions, today announced th...
2023-06-26 21:00
4321
Prenetics and Globally Renowned Scientist Prof. Dennis Lo Establish US$200m Joint Venture "Insighta" for Breakthrough Multi-Cancer Early Detection Screening
Company will Host Conference Call to Discuss the Transaction on June 26 at 8:30 a.m. EDT - Insighta is a 50/50 Joint Venture by Prenetics and Professor Dennis Lo. - Insighta is powered by technology developed by the Centre for Novostics which is supported by the InnoHK Initiative of the Innovati...
2023-06-26 08:45
4203
Ascletis Announces Poster Presentation of Phase II Study of ASC42 FXR Agonist for Functional Cure of Chronic Hepatitis B at EASL CONGRESS 2023
HANGZHOU and SHAOXING, China, June 26, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "Ascletis") today announces the poster presentation of ASC42, a novel farnesoid X receptor (FXR) agonist, in combination with PEGylated interferon (PEG-IFN) and entecavir (ETV) in chronic hepatitis B (...
2023-06-26 08:10
4544
Innovent and RemeGen Enter into Clinical Trial Collaboration Investigating Combination Therapy of TYVYT® (sintilimab injection) and Novel ADC Candidates for Advanced Solid Tumors in China
ROCKVILLE, Md. and SUZHOU, China, June 26, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology an...
2023-06-26 08:00
5150
Brii Biosciences Announces Entry into Definitive Agreements from Sale of its Equity Interest in Qpex Biopharma and Acquiring Exclusive Global Rights for BRII-693
Company acquires exclusive global rights of the novel lipopeptide BRII-693 for the difficult to treat MDR/XDR gram-negative bacterial infections Company returns Greater China rights to Qpex Biopharma of beta-lactamase inhibitor QPX7728-based products Company to receive ~$24M upfront cash payme...
2023-06-26 07:30
4557
Brii Bio Announces New Data from Partners Underscoring Potential for HBV Functional Cure at EASL™ Congress 2023
Late-breaking data from BRII-835 + PEG-IFN-a study demonstrate anti-HBs titers at the end of treatment were associated with sustained HBsAg loss 24 weeks after the end of treatment New data show more robust and persistent anti-HBs titers following vaccination with VBI's 3-antigen prevention vac...
2023-06-25 20:00
5651
Sciwind Biosciences to Highlight Positive Clinical Data for GLP-1 Peptide Agonist Ecnoglutide (XW003) at the American Diabetes Association (ADA) 83rd Annual Conference
* Results from three clinical studies show ecnoglutide to be safe and well-tolerated, and demonstrate robust therapeutic effects in overweight/obese and type 2 diabetes patients * On-going Phase 3 clinical trials in Chinese patients with type 2 diabetes and obesity have achieved target enroll...
2023-06-24 10:00
5734
European Wellness Signs MOU with Tianyou to Expand Education, Research and Development, and Healthcare in China.
BEIJING, June 23, 2023 /PRNewswire/ -- European Wellness Academy (EWA), the Malaysian educational arm of European Wellness Biomedical Group (EW Group), and Tianyou (Macau) Group Co., have signed a Memorandum of Understanding (MOU) to enhance the education, research and development, and healthcare...
2023-06-23 17:52
4687
Week's Top Stories
Most Reposted
Visa returns as title sponsor for 2026 MAMA AWARDS; Visa Presale registration begins 13 October
[Picked up by 315 media titles]
2026-10-13 10:00
Agoda and Emerging Travel Group Enter Strategic Partnership
[Picked up by 293 media titles]
2026-10-15 16:00Food & Hospitality Asia 2027 Redefining Excellence: The Premier Platform for Food & Beverage and Hospitality Innovation
[Picked up by 282 media titles]
2026-10-15 10:00SALMON SECURES $140 MILLION (PHP 8.8 BILLION) TO DOUBLE DOWN ON THE GROWTH OPPORTUNITY IN THE PHILIPPINES
[Picked up by 282 media titles]
2026-10-19 13:18
Leading Asian DMC Discova to Attend ITB Asia 2026
[Picked up by 280 media titles]
2026-10-15 12:59
Most Read
Sonilo Raises $11M to Build the AI-Native Audio Stack for Video
2026-10-15 00:00
25064
Visa returns as title sponsor for 2026 MAMA AWARDS; Visa Presale registration begins 13 October
2026-10-13 10:00
24708
Agoda and Emerging Travel Group Enter Strategic Partnership
2026-10-15 16:00
14197